More Indian Sites Under U.S. FDA Lens? Wockhardt Slapped With Import Alert On Injectables Site
This article was originally published in PharmAsia News
Executive Summary
In the wake of the Ranbaxy settlement, Wockhardt is the latest Indian company to be issued an import alert for alleged GMP violations.
You may also be interested in...
Ranbaxy Reports Corrections At Dewas Plant To U.S. FDA; Hopes Import Restrictions Will Be Lifted Soon
MUMBAI - Part of Ranbaxy's troubles with its manufacturing units in India may be coming to an end in the next few months; the company has filed an exhaustive report with the U.S. FDA on corrections made at its manufacturing facilities at Dewas
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.